

# Thomas John

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8808239/thomas-john-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

97  
papers

3,519  
citations

27  
h-index

58  
g-index

114  
ext. papers

4,883  
ext. citations

6.1  
avg, IF

5.27  
L-index

| #  | Paper  | IF   | Citations |
|----|--|------|-----------|
| 97 | Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with Fusion-Positive Solid Tumors.. <i>Clinical Cancer Research</i> , <b>2022</b> ,  | 12.9 | 10        |
| 96 | First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA.. <i>International Journal of Clinical Oncology</i> , <b>2022</b> , 27, 695-706 | 4.2  | 0         |
| 95 | SMARCB1/INI1-deficient primary lung carcinoma with hepatic metastasis.. <i>Pathology</i> , <b>2022</b> ,   | 1.6  | 0         |
| 94 | Regulation of the antigen presentation machinery in cancer and its implication for immune surveillance.. <i>Biochemical Society Transactions</i> , <b>2022</b> ,   | 5.1  | 2         |
| 93 | Imaging immunity in patients with cancer using positron emission tomography.. <i>Npj Precision Oncology</i> , <b>2022</b> , 6, 24  | 9.8  | 0         |
| 92 | Incorporating circulating tumor DNA detection to radiographic assessment for treatment response in advanced EGFR-mutant lung cancer. <i>Lung Cancer</i> , <b>2021</b> , 163, 14-18   | 5.9  | 0         |
| 91 | Uncommon EGFR mutations in non-small-cell lung cancer: A systematic literature review of prevalence and clinical outcomes.. <i>Cancer Epidemiology</i> , <b>2021</b> , 76, 102080  | 2.8  | 0         |
| 90 | Expression of EGFR and conformational forms of EGFR in malignant pleural mesothelioma and its impact on survival. <i>Lung Cancer</i> , <b>2021</b> , 153, 35-41  | 5.9  | 3         |
| 89 | Controversies in the role of radiotherapy in pleural mesothelioma. <i>Translational Lung Cancer Research</i> , <b>2021</b> , 10, 2079-2087   | 4.4  | 1         |
| 88 | Clinical utility of plasma EGFR mutation detection with quantitative PCR in advanced lung cancer: A meta-analysis. <i>Lung Cancer</i> , <b>2021</b> , 154, 113-117   | 5.9  | 2         |
| 87 | A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma. <i>Cell Death Discovery</i> , <b>2021</b> , 7, 122   | 6.9  | 5         |
| 86 | EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non-Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , <b>2021</b> , 22, e859-e869   | 4.9  | 6         |
| 85 | Immunotherapy in oncogene addicted non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , <b>2021</b> , 10, 2736-2751   | 4.4  | 2         |
| 84 | A narrative review of combined stereotactic ablative radiotherapy and immunotherapy in metastatic non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , <b>2021</b> , 10, 2766-2778  | 4.4  | 1         |
| 83 | Immune Checkpoint Inhibition With Chemoradiotherapy in Stage III Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis of Safety Results. <i>Clinical Lung Cancer</i> , <b>2021</b> , 22, 74-82  | 4.9  | 4         |
| 82 | The role of BCL-2 family proteins and therapeutic potential of BH3-mimetics in malignant pleural mesothelioma. <i>Expert Review of Anticancer Therapy</i> , <b>2021</b> , 21, 413-424  | 3.5  | 4         |
| 81 | First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , <b>2021</b> , 22, 198-211 | 21.7 | 244       |

|    |  |      |                 |
|----|--|------|-----------------|
| 80 | Significant detection of new germline pathogenic variants in Australian Pancreatic Cancer Screening Program participants. <i>Hereditary Cancer in Clinical Practice</i> , <b>2021</b> , 19, 33   | 2.3  | 1               |
| 79 | Analysis of angiogenic and stromal biomarkers in a large malignant mesothelioma cohort. <i>Lung Cancer</i> , <b>2020</b> , 150, 1-8  | 5.9  | 3               |
| 78 | Targeting and Efficacy of Novel mAb806-Antibody-Drug Conjugates in Malignant Mesothelioma. <i>Pharmaceuticals</i> , <b>2020</b> , 13,  | 5.2  | 4               |
| 77 | NTRK and ALK rearrangements in malignant pleural mesothelioma, pulmonary neuroendocrine tumours and non-small cell lung cancer. <i>Lung Cancer</i> , <b>2020</b> , 146, 154-159  | 5.9  | 9               |
| 76 | A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer. <i>Lung Cancer</i> , <b>2020</b> , 142, 34-40   | 5.9  | 16              |
| 75 | Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 9501-9501 | 2.2  | 87              |
| 74 | Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 9512-9512   | 2.2  | 41              |
| 73 | Nivolumab resulting in persistently elevated troponin levels despite clinical remission of myocarditis and myositis in a patient with malignant pleural mesothelioma: case report. <i>Translational Lung Cancer Research</i> , <b>2020</b> , 9, 360-365                                  | 4.4  | 6               |
| 72 | Occult Gastrointestinal Perforation in a Patient With EGFR-Mutant Non-Small-Cell Lung Cancer Receiving Combination Chemotherapy With Atezolizumab and Bevacizumab: Brief Report. <i>Clinical Lung Cancer</i> , <b>2020</b> , 21, e57-e60   | 4.9  | 2               |
| 71 | Overall Survival with Osimertinib in Untreated, -Mutated Advanced NSCLC. <i>New England Journal of Medicine</i> , <b>2020</b> , 382, 41-50   | 59.2 | 77 <sup>1</sup> |
| 70 | Preliminary study highlights the potential of immune checkpoint inhibitors in sarcomatoid mesothelioma. <i>Translational Lung Cancer Research</i> , <b>2020</b> , 9, 639-645   | 4.4  | 7               |
| 69 | Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody-Drug Conjugate. <i>Molecular Cancer Therapeutics</i> , <b>2020</b> , 19, 2117-2125   | 6.1  | 11              |
| 68 | Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. <i>Lancet Oncology</i> , <b>2020</b> , 21, 1213-1223  | 21.7 | 53              |
| 67 | BCL-XL is an actionable target for treatment of malignant pleural mesothelioma. <i>Cell Death Discovery</i> , <b>2020</b> , 6, 114   | 6.9  | 8               |
| 66 | Effect of Reasons for Screen Failure on Subsequent Treatment Outcomes in Cancer Patients Assessed for Clinical Trials. <i>Oncology</i> , <b>2019</b> , 97, 270-276   | 3.6  | 1               |
| 65 | Impact of universal immunohistochemistry on Lynch syndrome diagnosis in an Australian colorectal cancer cohort. <i>Internal Medicine Journal</i> , <b>2019</b> , 49, 1278-1284   | 1.6  | 2               |
| 64 | Standard dose osimertinib for erlotinib refractory T790M-negative -mutant non-small cell lung cancer with leptomeningeal disease. <i>Journal of Thoracic Disease</i> , <b>2019</b> , 11, 1756-1764   | 2.6  | 5               |
| 63 | BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival. <i>Cell Death and Disease</i> , <b>2019</b> , 10, 342  | 9.8  | 81              |

|    |   |      |     |
|----|---|------|-----|
| 62 | Epidermal growth factor receptor (EGFR)-targeted therapies in mesothelioma. <i>Expert Opinion on Drug Delivery</i> , <b>2019</b> , 16, 441-451  | 8    | 9   |
| 61 | Mesenchyme to epithelial transition protein expression, gene copy number and clinical outcome in a large non-small cell lung cancer surgical cohort. <i>Translational Lung Cancer Research</i> , <b>2019</b> , 8, 167-175                             | 4.4  | 4   |
| 60 | In Reply to Leone. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, e22-e23  | 8.9  |     |
| 59 | Personalized Chemosensitivity Assays for Mesothelioma: Are They Worth the Effort?. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 1513-1515  | 12.9 |     |
| 58 | Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 841-849  | 2.2  | 291 |
| 57 | Mismatch Repair Protein Defects and Microsatellite Instability in Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, 1588-1594   | 8.9  | 23  |
| 56 | EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer. <i>Lung Cancer</i> , <b>2018</b> , 126, 133-138 | 5.9  | 21  |
| 55 | Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, 1784-1791  | 8.9  | 57  |
| 54 | Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: An early decision analytic model of multiplex targeted sequencing. <i>Lung Cancer</i> , <b>2017</b> , 107, 22-35                             | 5.9  | 21  |
| 53 | Standard of care in immunotherapy trials: Challenges and considerations. <i>Human Vaccines and Immunotherapeutics</i> , <b>2017</b> , 13, 2164-2178   | 4.4  | 4   |
| 52 | The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, 850-859   | 8.9  | 64  |
| 51 | Outcomes for patients with synchronous and metachronous primary lung cancer after diagnosis of head and neck cancer. <i>Head and Neck</i> , <b>2017</b> , 39, 1544-1549   | 4.2  | 3   |
| 50 | Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. <i>Lancet Respiratory Medicine</i> , <b>2017</b> , 5, 891-902                  | 35.1 | 56  |
| 49 | Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3591-3600                     | 2.2  | 93  |
| 48 | Attitudes of patients and physicians on repeat biopsies for lung cancer. <i>Expert Review of Quality of Life in Cancer Care</i> , <b>2017</b> , 2, 181-202  |      |     |
| 47 | De novo activating epidermal growth factor mutations (EGFR) in small-cell lung cancer. <i>Internal Medicine Journal</i> , <b>2017</b> , 47, 1071-1074   | 1.6  | 3   |
| 46 | Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, 1728-1732   | 8.9  | 99  |
| 45 | Australian recommendations for EGFR T790M testing in advanced non-small cell lung cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2017</b> , 13, 296-303  | 1.9  | 12  |

|    |  |      |    |
|----|--|------|----|
| 44 | The ADAM Trial: Visiting the Road Less Traveled. <i>JAMA Oncology</i> , <b>2017</b> , 3, 66-67   | 13.4 | 0  |
| 43 | Patient-Derived Xenograft Establishment from Human Malignant Pleural Mesothelioma. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 1060-1067   | 12.9 | 32 |
| 42 | Outcomes of anti-PD-1 therapy in mesothelioma and correlation with PD-L1 expression.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 8514-8514  | 2.2  | 11 |
| 41 | Promoter hypomethylation of NY-ESO-1, association with clinicopathological features and PD-L1 expression in non-small cell lung cancer. <i>Oncotarget</i> , <b>2017</b> , 8, 74036-74048                 | 3.3  | 10 |
| 40 | Lung cancer in 2016: immunotherapy comes of age. <i>Lancet Respiratory Medicine</i> , <b>2016</b> , 4, 947-949   | 35.1 | 9  |
| 39 | Testicular metastasis from ALK-rearranged non-small cell lung cancer. <i>Cancer Treatment and Research Communications</i> , <b>2016</b> , 9, 32-34   | 2    |    |
| 38 | Calretinin but not caveolin-1 correlates with tumour histology and survival in malignant mesothelioma. <i>Pathology</i> , <b>2016</b> , 48, 660-665  | 1.6  | 10 |
| 37 | Combination approaches in NSCLC involving immune checkpoint inhibitors. <i>Lung Cancer Management</i> , <b>2016</b> , 5, 163-171   | 2.6  | 1  |
| 36 | Digital PCR of Genomic Rearrangements for Monitoring Circulating Tumour DNA. <i>Advances in Experimental Medicine and Biology</i> , <b>2016</b> , 924, 139-146   | 3.6  | 5  |
| 35 | Current and Evolving Methods to Visualize Biological Data in Cancer Research. <i>Journal of the National Cancer Institute</i> , <b>2016</b> , 108,   | 9.7  | 13 |
| 34 | PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC. <i>PLoS ONE</i> , <b>2016</b> , 11, e0153954   | 3.7  | 53 |
| 33 | Severe Psoriasis Flare After Anti-Programmed Death Ligand 1 (PD-L1) Therapy for Metastatic Non-Small Cell Lung Cancer (NSCLC). <i>Journal of Immunotherapy</i> , <b>2016</b> , 39, 202-4                 | 5    | 25 |
| 32 | Temporal changes of EGFR mutations and T790M levels in tumour and plasma DNA following AZD9291 treatment. <i>Lung Cancer</i> , <b>2016</b> , 98, 29-32   | 5.9  | 24 |
| 31 | Targeting the vasculature: anti-angiogenic agents for malignant mesothelioma. <i>Expert Review of Anticancer Therapy</i> , <b>2016</b> , 16, 1235-1245   | 3.5  | 6  |
| 30 | Role of immunotherapy in lung cancer: Preliminary results of new vaccines and immune checkpoint inhibitors. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2015</b> , 11 Suppl 1, 2-8             | 1.9  | 3  |
| 29 | Vortex Keratopathy Presumed Secondary to AZD9291. <i>Journal of Thoracic Oncology</i> , <b>2015</b> , 10, 1807-8   | 8.9  | 13 |
| 28 | "Cancer 2015": A Prospective, Population-Based Cancer Cohort-Phase 1: Feasibility of Genomics-Guided Precision Medicine in the Clinic. <i>Journal of Personalized Medicine</i> , <b>2015</b> , 5, 354-69 | 3.6  | 8  |
| 27 | A critical re-assessment of DNA repair gene promoter methylation in non-small cell lung carcinoma. <i>Scientific Reports</i> , <b>2014</b> , 4, 4186   | 4.9  | 27 |

|    |  |      |     |
|----|--|------|-----|
| 26 | Development of a novel, quantitative protein microarray platform for the multiplexed serological analysis of autoantibodies to cancer-testis antigens. <i>International Journal of Cancer</i> , <b>2014</b> , 135, 1842-51                     | 7.5  | 16  |
| 25 | Mapping of actionable mutations to histological subtype domains in lung adenocarcinoma: implications for precision medicine. <i>Oncotarget</i> , <b>2014</b> , 5, 2107-15  | 3.3  | 18  |
| 24 | Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. <i>Clinical Epidemiology</i> , <b>2014</b> , 6, 423-32  | 5.9  | 90  |
| 23 | Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP. <i>Cancer Cell</i> , <b>2013</b> , 23, 618-33   | 24.3 | 107 |
| 22 | Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non-small cell lung cancer. <i>Cancer Medicine</i> , <b>2013</b> , 2, 916-24                                    | 4.8  | 22  |
| 21 | Do randomized acupuncture studies in patients with cancer need a sham acupuncture control arm?. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 2057-8   | 2.2  | 15  |
| 20 | Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients. <i>Journal of Thoracic Oncology</i> , <b>2013</b> , 8, 461-8 | 8.9  | 87  |
| 19 | The role of Cancer-Testis antigens as predictive and prognostic markers in non-small cell lung cancer. <i>PLoS ONE</i> , <b>2013</b> , 8, e67876   | 3.7  | 25  |
| 18 | Should we screen for lung cancer in Australia?. <i>Medical Journal of Australia</i> , <b>2013</b> , 199, 586   | 4    |     |
| 17 | Exploiting the noise: improving biomarkers with ensembles of data analysis methodologies. <i>Genome Medicine</i> , <b>2012</b> , 4, 84   | 14.4 | 14  |
| 16 | Paraneoplastic leukocytoclastic vasculitis as an initial presentation of malignant pleural mesothelioma: a case report. <i>Journal of Medical Case Reports</i> , <b>2012</b> , 6, 261  | 1.2  | 6   |
| 15 | Characterization of lymphomas developing in immunodeficient mice implanted with primary human non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2012</b> , 7, 1101-8  | 8.9  | 34  |
| 14 | Loss of phosphatase and tensin homolog protein expression is an independent poor prognostic marker in lung adenocarcinoma. <i>Journal of Thoracic Oncology</i> , <b>2012</b> , 7, 1513-21  | 8.9  | 41  |
| 13 | Bronchoepidural Fistula in a man with actinomycosis complicated non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2011</b> , 6, 1761-2  | 8.9  | 1   |
| 12 | Pharmacogenetic and germline prognostic markers of lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2011</b> , 6, 296-304   | 8.9  | 31  |
| 11 | The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 134-41                                       | 12.9 | 131 |
| 10 | Re: Gene expression-based prognostic signatures in lung cancer: ready for clinical use?. <i>Journal of the National Cancer Institute</i> , <b>2010</b> , 102, 1677-8; author reply 1678-9  | 9.7  | 7   |
| 9  | Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells. <i>Cancer Immunology, Immunotherapy</i> , <b>2009</b> , 58, 1635-46   | 7.4  | 62  |

|   |  |          |
|---|--|----------|
| 8 | Understanding prognostic gene expression signatures in lung cancer. <i>Clinical Lung Cancer</i> , <b>2009</b> , 10, 331-40   | 49       |
| 7 | Molecular predictive and prognostic markers in non-small-cell lung cancer. <i>Lancet Oncology</i> , <b>2009</b> , 10, 1001-10  | 21.7 167 |
| 6 | Distinctive localization of antigen-presenting cells in human lymph nodes. <i>Blood</i> , <b>2009</b> , 113, 1257-67   | 2.2 65   |
| 5 | Predicting clinical outcome through molecular profiling in stage III melanoma. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 5173-80                                       | 12.9 58  |
| 4 | ECSA/DPPA2 is an embryo-cancer antigen that is coexpressed with cancer-testis antigens in non-small cell lung cancer. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 3291-8 | 12.9 25  |
| 3 | Immunotherapy of advanced or metastatic melanoma. <i>Clinical Advances in Hematology and Oncology</i> , <b>2007</b> , 5, 994-1006  | 0.6 10   |
| 2 | Ventricular metastasis resulting in disseminated intravascular coagulation. <i>World Journal of Surgical Oncology</i> , <b>2005</b> , 3, 29                                      | 3.4 3    |
| 1 | Cancer Testis Antigens161-177  | 2        |